Tech Company Financing Transactions
Adenosine Therapeutics Funding Round
Novartis BioVenture Fund participated in a $14 million Series C funding round for Adenosine Therapeutics. The financing was announced on 6/18/2007.
Transaction Overview
Company Name
Announced On
6/18/2007
Transaction Type
Venture Equity
Amount
$14,000,000
Round
Series C
Investors
Proceeds Purpose
"This relationship will accelerate the clinical development of our family of A2B antagonists that have the potential to offer new oral treatment options for patients suffering from Type II diabetes and asthma," said Robert S. Capon, Chief Executive Officer and co-founder of Adenosine Therapeutics. "Collaborating with Novartis allows ATL to complement its internal research capabilities with those of this well-respected leader in the pharmaceutical industry and provides robust financing to take the program forward into clinical development."
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
P.O. Box 4632
Charlottesville, VA 22905
USA
Charlottesville, VA 22905
USA
Phone
Website
Email Address
Overview
Adenosine Therapeutics (AT), located in Charlottesville, VA, is a drug discovery and development company that was co-founded in 1999 by University of Virginia (UVa) Professor, Joel Linden and entrepreneur, Robert Capon (one of three cofounders of Virologic, NASDAQ: VLGC.)
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Joel Linden
Chief Executive Officer
Robert Capon
Chief Operating Officer
William Stilley
Controller
Robert Owen
Vice President
William Gray
Vice President
Robert Thompson
Vice President
Shannon Williams
VP - Manufacturing
Jayson Rieger
Browse more venture capital transactions:
Prev: 6/18/2007: K2 Network venture capital transaction
Next: 6/18/2007: Bag Borrow or Steal venture capital transaction
Share this article
News on VC Transactions
Our team works diligently to report on every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs